147 related articles for article (PubMed ID: 34944889)
1. Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin.
Mould RC; van Vloten JP; AuYeung AWK; Walsh SR; de Jong J; Susta L; Mutsaers AJ; Petrik JJ; Wood GA; Wootton SK; Karimi K; Bridle BW
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944889
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model.
Wang YQ; Zhang HH; Liu CL; Wu H; Wang P; Xia Q; Zhang LX; Li B; Wu JX; Yu B; Gu TJ; Yu XH; Kong W
Int Immunopharmacol; 2013 Sep; 17(1):9-17. PubMed ID: 23624214
[TBL] [Abstract][Full Text] [Related]
3. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
[TBL] [Abstract][Full Text] [Related]
4. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.
Guo Q; Wang L; Xu P; Geng F; Guo J; Dong L; Bao X; Zhou Y; Feng M; Wu J; Wu H; Yu B; Zhang H; Yu X; Kong W
Oncoimmunology; 2020 Nov; 9(1):1841392. PubMed ID: 33224629
[TBL] [Abstract][Full Text] [Related]
5. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy.
Tzelepis F; Birdi HK; Jirovec A; Boscardin S; Tanese de Souza C; Hooshyar M; Chen A; Sutherland K; Parks RJ; Werier J; Diallo JS
Mol Ther Oncolytics; 2020 Dec; 19():240-252. PubMed ID: 33209979
[TBL] [Abstract][Full Text] [Related]
7. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model.
He R; Yang X; Liu C; Chen X; Wang L; Xiao M; Ye J; Wu Y; Ye L
Cell Mol Immunol; 2018 Sep; 15(9):815-826. PubMed ID: 28287115
[TBL] [Abstract][Full Text] [Related]
8. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
9. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
10. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
J Virol; 2021 May; 95(12):. PubMed ID: 33789991
[TBL] [Abstract][Full Text] [Related]
11. Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines.
Hu Z; Jiang W; Gu L; Qiao D; Shu T; Lowrie DB; Lu SH; Fan XY
J Mol Med (Berl); 2019 Dec; 97(12):1685-1694. PubMed ID: 31786669
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
[TBL] [Abstract][Full Text] [Related]
13. DNA/Ad5 vaccination with SIV epitopes induced epitope-specific CD4⁺ T cells, but few subdominant epitope-specific CD8⁺ T cells.
Vojnov L; Bean AT; Peterson EJ; Chiuchiolo MJ; Sacha JB; Denes FS; Sandor M; Fuller DH; Fuller JT; Parks CL; McDermott AB; Wilson NA; Watkins DI
Vaccine; 2011 Oct; 29(43):7483-90. PubMed ID: 21839132
[TBL] [Abstract][Full Text] [Related]
14. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
[TBL] [Abstract][Full Text] [Related]
15. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.
Fournillier A; Frelin L; Jacquier E; Ahlén G; Brass A; Gerossier E; Holmström F; Broderick KE; Sardesai NY; Bonnefoy JY; Inchauspé G; Sällberg M
J Infect Dis; 2013 Sep; 208(6):1008-19. PubMed ID: 23776192
[TBL] [Abstract][Full Text] [Related]
16. Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.
George JA; Eo SK
Immune Netw; 2011 Oct; 11(5):268-80. PubMed ID: 22194710
[TBL] [Abstract][Full Text] [Related]
17. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of different heterologous prime-boost immunization strategies against Babesia bovis using viral vectored and protein-adjuvant vaccines based on a chimeric multi-antigen.
Jaramillo Ortiz JM; Molinari MP; Gravisaco MJ; Paoletta MS; Montenegro VN; Wilkowsky SE
Vaccine; 2016 Jul; 34(33):3913-9. PubMed ID: 27269058
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
20. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
